Horizon Therapeutics announced that the FDA has approved an update to the Indications and usage section of the Tepezza label to specify its use for the treatment of "Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HZNP:
- Horizon announces results from Tepezza trial in patients with CAS, TED
- Viridian Therapeutics initiated with a Buy at Stifel
- Horizon Therapeutics presents MRI imaging data from Phase 3 trial of UPLIZNA
- Wells Fargo upgrades Amgen to Overweight, lowers target to $265
- Horizon Therapeutics announces results from real-world analysis of TEPEZZA